BDNF Val66Met polymorphism is associated with negative symptoms in early-onset schizophrenia spectrum and other psychotic disorders

dc.authoridcengiz, mujgan/0000-0003-1030-5425
dc.authoridESEROGLU SOYLEMEZ, Tugba/0000-0002-6921-4985
dc.authoridTekden, Mehmet/0000-0002-3085-1725
dc.authoridBayoglu, Burcu/0000-0001-6568-6398
dc.authoridAksoyer Sezgin, Saadet Busra/0000-0002-8338-9546
dc.contributor.authorKaracetin, G.
dc.contributor.authorBayoglu, B.
dc.contributor.authorSoylemez, T. Eseroglu
dc.contributor.authorTopal, M.
dc.contributor.authorKoc, E. Bulanik
dc.contributor.authorTekden, M.
dc.contributor.authorErmis, C.
dc.date.accessioned2024-09-29T15:55:17Z
dc.date.available2024-09-29T15:55:17Z
dc.date.issued2022
dc.departmentKarabük Üniversitesien_US
dc.description.abstractBackground and Objectives: To investigate the clinical characteristics of adolescents with early-onset full psychotic disorders either with Brain-derived neurotrophic factor (BDNF) Val66Met (rs6265) or DRD2/ANKK1 Taq1A (rs1800497) polymorphisms. Method: 101 cases with early-onset schizophrenia (EOS) or other psychotic spectrum disorders (SSD) and 150 healthy controls were included in the current study. Using the Positive and Negative Symptom Scale (PANSS), patient subgroups were compared for their psychotic symptoms, age-onset, duration of untreated illness, and family history of psychiatric disorders. The real-time polymerase chain reaction (RT-PCR) was implemented for genotyping procedures. Results: Study groups and patient subgroups were similar regarding their sociodemographic characteristics (16.4 +/- 2.6 years, 62.2% male for all participants). Results did not reveal any difference between patients and healthy controls for DRD2/ANKK1 Taq1A and BDNF Val66Met genotypes. Patients with A1A2 (Gly/Lys) allele reported higher rates of substance use compared to A2A2 (Glu/Glu) counterparts. Other clinical variables were found similar. EOS/SSD group with Val66Met heterozygote allele revealed lower levels of negative symptoms than Val/Val homozygotes. Conversely, the age onset of full psychotic disorder, total positive symptom score, and total general psychopathology score of PANSS were found comparable between Val/Met and Val/Val groups. In the logistic regression model, Glu/Lys genotypes remained significant for the presence of substance use. Conclusion: The interaction between substance use and the DRD2 gene should be investigated for the development of early-onset psychotic disorders. BDNF Val66Met polymorphism also could be a disease-modifying factor for the presence of negative symptoms. (C) 2021 Asociacion Universitaria de Zaragoza para el Progreso de la Psiquiatria y la Salud Mental. Published by Elsevier Espana, S.L.U. All rights reserved.en_US
dc.description.sponsorship[42496]; [54033]en_US
dc.description.sponsorshipThis study was funded by the Scientific Research ProjectsCoordination Unit of Istanbul University-Cerrahpasa. Projectnumbers: 42496, 54033.en_US
dc.identifier.doi10.1016/j.ejpsy.2021.04.002
dc.identifier.endpage34en_US
dc.identifier.issn0213-6163
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85115968582en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage26en_US
dc.identifier.urihttps://doi.org/10.1016/j.ejpsy.2021.04.002
dc.identifier.urihttps://hdl.handle.net/20.500.14619/4575
dc.identifier.volume36en_US
dc.identifier.wosWOS:000768703500003en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherElsevier Espana Sluen_US
dc.relation.ispartofEuropean Journal of Psychiatryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDRD2/ANKK1 Taq1A genotypesen_US
dc.subjectBDNF Val66Met genotypesen_US
dc.subjectEarly-onset schizophreniaen_US
dc.titleBDNF Val66Met polymorphism is associated with negative symptoms in early-onset schizophrenia spectrum and other psychotic disordersen_US
dc.typeArticleen_US

Dosyalar